JANX januxrx.com: Enterprise Value to EBITDA Ratio
Janux Therapeutics (JANX) possesses high scientific authority in the development of precision anti-tumor agents. Despite current molecule development costs, the future potential for mass sales promises global leadership. The company's dynamic EV/EBITDA metric visualizes this balance, where the value 0.00 determines this level. Price stability is supported by loyal T-cell therapy experts whose qualifications prevent talent attrition.
Summary analytical data breakdowns for Janux Pharma (JANX)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Janux Therapeutics|JANX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Janux Therapeutics Inc|JANX - Company Aggregate Debts|Debt to Book Capitalization Ratio Janux Pharma|JANX - Company Long-Term Indebtedness|Company Short-Term Debt Janux Therapeutics|Quick Liquidity Indicator januxrx.com
- financial results and valuation multiples details:
JANX - Annual Net Income|Future Profit Janux Therapeutics|JANX - Market Price to Net Income Ratio|Forward P/E Multiple Janux Therapeutics, Inc.|JANX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Janux Corp|JANX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Janux Therapeutics|JANX - Earnings per share for the trailing year|Quarterly EPS earnings growth januxrx.com|JANX - Earnings growth in current year|Net earnings per share growth forecast for next year Janux Therapeutics
- sales volume and revenue indicators:
Fundamental company analysis:JANX (Janux Therapeutics, Inc.)
This indicator compares the total enterprise value with its operating profit before depreciation and amortization, allowing for an assessment of capital management efficiency and debt load. For Janux Therapeutics (JANX), which focuses on early-stage research and basic bio-waste utilization, the EV/EBITDA ratio, accounting for capital structure, serves as a measure of the business's financial stability on the path toward the commercialization of its developments.
Competitor analysis for Janux Therapeutics
ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|RCUS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ZYME (Zymeworks)|TNGX: EV/EBITDA Multiple|IOVA - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization immatics.com|Enterprise Value to EBITDA Ratio xencor.com (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics Inc (CMPX)|Enterprise Value to EBITDA Ratio Replimune Corp REPL|Lyell - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma S.A IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen) - Enterprise Value to Operating Income Before Depreciation|IO Biotech Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Sutro Bio (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma Inc.)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Bio|Liminatus Pharma (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics NV - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics
